Skip to content
OpenCapital
Get started

CONMED CNMD Other, net

Other, net at other companies

Stryker logo
StrykerSYK
-$34M-41.7%
Boston Scientific logo
Boston ScientificBSX
$3M+130%
Vericel logo
VericelVCEL
-$21K-425%
Johnson & Johnson logo
Johnson & JohnsonJNJ
——
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
——
Medtronic logo
MedtronicMDT
——

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.07B-35.6%
Enterprise value$1.89B-24.5%
P/E19.4×+5.5×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's other, net?
CONMED (CNMD) reported other, net of $828K in Q1 2026.
How has CONMED's other, net changed year-over-year?
CONMED's other, net increased by 278.4% year-over-year, from -$464K to $828K.
What is the long-term trend for CONMED's other, net?
Over 3 years (2022 to 2025), CONMED's other, net has grown at a -72.8% compound annual growth rate (CAGR), from $8.48M to $170K.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.